Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

non-alcoholic steatohepatitis drugs

- PMLiVE

BMS links up with Molecular Templates for oncology research collaboration

Deal could be worth up to $1.3bn in milestone payments

- PMLiVE

BMS and Exelixis’ Opdivo/Cabometyx shows continued benefit in kidney cancer

Combination also demonstrated benefit in sarcomatoid subgroup with poor prognoses

- PMLiVE

FDA approves BMS’ blood cancer CAR T therapy after delay

The FDA's approval of Breyanzi came a year after the start of the review

- PMLiVE

Gilead’s COVID-19 drug Veklury brought in almost $2bn in Q4

Antiviral drug also brought in $2.8bn for the full year

- PMLiVE

UPDATED: Gilead says remdesivir likely to be effective against new COVID-19 strains

FDA approved the antiviral drug for the treatment of hospitalised COVID-19 patients in October 2020

- PMLiVE

BMS gains FDA approval for second Opdivo combo in kidney cancer

BMS' Opdivo/Yervoy regimen was its first combo to be approved for advanced renal cell carcinoma

- PMLiVE

Gilead’s Jyseleca is given a NICE recommendation for rheumatoid arthritis

JAK inhibitor approved for use in moderate-to-severe RA

- PMLiVE

BMS aims for US approval of Opdivo combo in stomach cancer

US regulator has set a goal date for a decision on 25 May

- PMLiVE

Merck’s appeal to restore hepatitis C patent verdict against Gilead fails

US Supreme Court rejects Merck’s appeal over patent dispute verdict of $2.54bn

- PMLiVE

The search for effective drug treatments for COVID-19

PME talks to Julian Cole, Senior Director, Medical Affairs at Gilead Sciences

- PMLiVE

Kite and Oxford BioTherapeutics sign oncology research pact

Agreement will focus on five novel drug targets across a range of indications

- PMLiVE

Gilead set to acquire hepatitis specialist MYR for €1.15bn

Acquisition will see Gilead pick up HDV treatment Hepcludex

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links